Aclarion Inc（ACON）資訊與事件ACONAclarion Inc

Aclarion Publishes Nociscan Study Results with 87% Identification Rate

Aclarion announced the publication of an independent, peer-reviewed study in the European Spine Journal. Conducted by the London Spine Clinic, the study evaluated Nociscan against low-pressure provocative discography, the invasive procedure long considered the reference standard for identifying painful discs. The study compared the non-invasive Nociscan to discography in twenty consecutive patients being evaluated for surgical treatment, across 55 lumbar discs. Nociscan findings successfully identified painful discs, agreeing with discography in up to 87% of discs under a moderate threshold. At the study site, a three-disc Nociscan exam costs about GBP 2,040, versus roughly GBP 2,775 for an equivalent discogram. The authors, who noted the study's limited sample size, said larger, multi-center studies are being organized to build on the findings. "An agreement rate of up to 87% with an imperfect reference standard is a strong signal and exactly the kind of independent, real-world evidence that builds the case for physician adoption and payor support for Nociscan," said Ryan Bond, chief strategy officer.

Aclarion Reports 85% Year-over-Year Scan Volume Growth in Q3

Aclarion announced the publication of a shareholder letter from CEO Brent Ness covering Q3. The company reported 85% year-over-year scan volume growth in Q3, contributing to 117% growth for the nine months ended September 30. The European Spine Journal published peer-reviewed data supporting magnetic resonance spectroscopy as a potential viable alternative to provocative discography. The CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment. Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end. The company has $14.2M in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial. "The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can offer their patients with chronic low back pain," said Brent Ness, CEO.

Aclarion Announces NYU Langone Health as New Clinical Site in CLARITY Trial

Aclarion announced NYU Langone Health as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.